Tagged with Opinion,

USA Meghann Chilcott offers an introductory look at the potential of customer data platforms (CDPs) to transform the way pharmacy marketers reach out to an increasingly online customer base in the USA.   CDPs enable marketers to pool customer information together from various sources for the purpose of creating seamless, data-rich…

USA Carla Smith outlines the role that a value-based care (VBC) approach can have on both reducing healthcare costs and improving overall care delivery to patients in the USA. Smith highlights VBC’s benefits to patients, payers and pharma companies, but notes that physicians are still not necessarily convinced; meaning the adoption…

Opinion Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe – including the impending exit of the UK from the European Union – on pharmaceutical firms across the continent.   The right-leaning parties that will play a more prominent role in European politics are even…

Opinion David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness month.   Alzheimer’s disease is a complex chronic disease characterized biologically by the accumulation of extracellular protein plaques, neurofibrillary protein tangles, a loss of functional synaptic connections, and eventually…

China Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps into China and the potential impact of mutual insurance – whereby the insurance company is owned entirely by its policyholders…

Opinion Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful implementations, and explains why policy updates are so important to ensuring a more comprehensive rollout of these models around the globe.   We’re looking forward to being one customer of many…

Opinion Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics supply chain is standardized, transparent and dynamic, helping save the US healthcare system trillions of dollars.   Savings have totaled…

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) discusses the potential impact that new technological innovations will have on the drug development process.   A more technologically integrated approach is required that looks more holistically at the patient as an individual Whether we call it “Personalised”, “Precision”, “Stratified”, or “Tailored”, the age…

Europe From her vantage point as associate vice president for MSD’s Central & Eastern Europe (CEE) cluster, Gabriele Grom outlines the disparity that still exists in terms of access to cancer treatments across Europe and what must be done to bridge this gap.   Despite the existence of innovative treatments, cancer…

AI Axel Schumacher highlights the vital importance of AI and blockchain for the future success of pharmaceutical companies, the significant knowledge gap that currently exists within Big Pharma, and why, therefore, now is the time for these firms to invest in AI and blockchain start-ups.   While almost everyone is talking…

USA Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be conducted in order to ensure the safety of rare disease patients – many of them children – who are using CBD products for their…

AI Digital marketing expert Buck Dossey expounds the importance of soliciting user data to improve patient experiences and the ways in which AI can be utilised within this process.   Companies should start by thinking of ways to leverage unified data sets and digital access points to create and deliver connected,…